Suzanne Vernon

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
SuzanneVernon.jpeg

Suzanne D. Vernon, PhD, is the Research Liaison at Bateman Horne Center of Excellence which specializes in treatment and research for ME/CFS and Fibromyalgia[1] and the Chief Scientific Revolutionary of The BioCollective, a collaborative that provides storage and sales of microbiome samples for research and development.[2]

From November 2007 to May 2015, Dr. Vernon was the Scientific Director of Solve ME/CFS Initiative, formerly known as CFIDS Association of America.[3] While there she recognized that access to well-characterized clinical populations was a barrier to engaging more scientists in ME/CFS research. Thus, she started the Research Institute Without Walls (RIWW), "the first nonprofit patient-centered research initiative focused on identifying diagnostic biomarkers and disease-modifying treatment for ME/CFS.[1] The core of RIWW is the SolveCFS BioBank & Patient Registry.[4]

From May 1990 to October 2007, Dr. Vernon worked for the US Centers for Disease Control, first on the team investigating the human papillomavirus as an opportunistic infection in HIV-infected woman, and then in 1997, she became the CFS research group team leader, under William Reeves, MD, the Director of the CDC Chronic Fatigue Research Program.[5][6]

In 2005, Dr Vernon was one of the authors of the CDC case definition of CFS, commonly called the Reeves criteria.[7]

Talks and interviews[edit | edit source]

Studies and Articles[edit | edit source]

Online presence[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ 1.01.1 "Suzanne D. Vernon, PhD". Bateman Horne Center. Retrieved February 2, 2019.
  2. ↑ http://www.thebiocollective.com/about-us/
  3. ↑ "Suzanne D. Vernon Steps Down from Scientific Director Post". Solve ME/CFS Initiative. April 8, 2015. Retrieved February 2, 2019.
  4. ↑ "Advancing Science: A Case for Hope, A Look Ahead". Solve ME/CFS Initiative. Retrieved June 25, 2019.
  5. ↑ https://www.linkedin.com/in/suzanne-d-vernon-phd-2743a617
  6. ↑ Grady, Denise (August 8, 2012). "Dr. William C. Reeves, Who Sought Cause of Fatigue Syndrome, Dies at 69". The New York Times. ISSN 0362-4331. Retrieved February 2, 2019.
  7. ↑ 7.07.1 Reeves, William C; Wagner, Dieter; Nisenbaum, Rosane; Jones, James F; Gurbaxani, Brian; Solomon, Laura; Papanicolaou, Dimitris A; Unger, Elizabeth R; Vernon, Suzanne D (December 2005). "Chronic Fatigue Syndrome – A clinically empirical approach to its definition and study". BMC Medicine. 3: 19. doi:10.1186/1741-7015-3-19. ISSN 1741-7015.
  8. ↑ Reeves, W.C.; Lloyd, A.; Vernon, S.D.; Klimas, N.; Jason, L.A.; Bleijenberg, G.; Evengard, B.; White, P.D.; Nisenbaum, R.; Unger, E. (2003). "Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution". BMC Health Services Research. 3: 25. doi:10.1186/1472-6963-3-25.
  9. ↑ Whistler, Toni; Unger, Elizabeth R.; Nisenbaum, Rosane; Vernon, Suzanne D. (December 1, 2003). "Integration of gene expression, clinical, and epidemiologic data to characterize Chronic Fatigue Syndrome". Journal of Translational Medicine. 1: 10. doi:10.1186/1479-5876-1-10. ISSN 1479-5876. PMC 305360. PMID 14641939.
  10. ↑ Rajeevan, Mangalathu S.; Jones, James F.; Vernon, Suzanne D.; Unger, Elizabeth R.; Steinau, Martin (November 1, 2004). "Differential-display PCR of peripheral blood for biomarker discovery in chronic fatigue syndrome". Journal of Molecular Medicine. 82 (11): 750–755. doi:10.1007/s00109-004-0586-4. ISSN 1432-1440.
  11. ↑ Hickie, Ian; Davenport, Tracey; Wakefield, Denis; Vollmer-Conna, Ute; Cameron, Barbara; Vernon, Suzanne D; Reeves, William C; Lloyd, Andrew (September 16, 2006). "Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study". BMJ. 333 (7568): 575–. doi:10.1136/bmj.38933.585764.ae. PMC 1569956. PMID 16950834.
  12. ↑ Vernon, SD; Whistler, T; Cameron, B; Hickie, IB; Reeves, WC; Lloyd, A (2006). "Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr Virus". BMC Infectious Diseases. 6 (15). doi:10.1186/1471-2334-6-15. PMID 16448567.
  13. ↑ Fuite, Jim; Vernon, Suzanne; Broderick, Gordon (2008). "Neuroendocrine and immune network re-modeling in chronic fatigue syndrome: an exploratory analysis". Genomics. 92 (6): 393–9. doi:10.1016/j.ygeno.2008.08.008. PMID 18775774.
  14. ↑ Aspler, AL; Bolshin, C; Vernon, SD; Broderick, G (2008). "Evidence of inflammatory immune signaling in chronic fatigue syndrome: A pilot study of gene expression in peripheral blood". Behavioral and Brain Functions. 4: 44. doi:10.1186/1744-9081-4-44.
  15. ↑ Sorensen, Bristol; Jones, James F; Vernon, Suzanne D; Rajeevan, Mangalathu S (January 2009). "Transcriptional Control of Complement Activation in an Exercise Model of Chronic Fatigue Syndrome". Molecular Medicine. 15 (1–2): 34–42. doi:10.2119/molmed.2008.00098. PMC 2583111. PMID 19015737.
  16. ↑ Broderick, Gordon; Katz, Ben Z; Fernandes, Henrique; Fletcher, Mary Ann; Klimas, Nancy; Smith, Frederick A; O'Gorman, Maurice RG; Vernon, Suzanne D; Taylor, Renee (2012). "Cytokine expression profiles of immune imbalance in post-mononucleosis chronic fatigue". Journal of Translational Medicine. 10: 191. doi:10.1186/1479-5876-10-191.
  17. ↑ Irlbeck, David M.; Vernon, Suzanne D.; McCleary, K. Kimberly; Bateman, Lucinda; Klimas, Nancy G.; Lapp, Charles W.; Peterson, Daniel L.; Brown, James R.; Remlinger, Katja S.; Wilfret, David A.; Gerondelis, Peter (2014). "No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank". BMC Research Notes. 7: 461. doi:10.1186/1756-0500-7-461.
  18. ↑ Jason, Leonard A.; Sunnquist, Madison; Brown, Abigail; Evans, Meredyth; Vernon, Suzanne D.; Furst, Jacob D.; Simonis, Valerie (2014). "Examining case definition criteria for chronic fatigue syndrome and myalgic encephalomyelitis". Fatigue: Biomedicine, Health & Behavior. 2 (1): 40–56. doi:10.1080/21641846.2013.862993. PMC 3912876.
  19. ↑ Jason, L.A.; Sunnquist, M.; Brown, A.; Newton, J.L.; Strand, E.B.; Vernon, S.D. (2015). "Chronic fatigue syndrome versus systemic exertion intolerance disease". Fatigue: Biomedicine, Health & Behavior. 3 (3): 127–141. doi:10.1080/21641846.2015.1051291.
  20. ↑ Jason, LA; Kot, B; Sunnquist, M; Brown, A; Reed, J; Furst, J; Newton, JL; Strand, EB; Vernon, SD (2015). "Comparing and Contrasting Consensus versus Empirical Domains". Fatigue: biomedicine, health & behavior. 3 (2): 63–74. doi:10.1080/21641846.2015.1017344. PMID 26977374.
  21. ↑ Shukla, SK; Cook, DB; Meyer, J; Vernon, SD; Le, T; Clevidence, D; Robertson, CE; Schrodi, SJ; Yale, S; Frank, DN (2015). "Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". PLoS One. 10 (12): e0145453. doi:10.1371/journal.pone.0145453. PMC 468420.
  22. ↑ Murdock, KW; Wang, XS; Shi, Q; Cleeland, CS; Fagundes, CP; Vernon, Suzanne D. (2016). "The utility of patient-reported outcome measures among patients with myalgic encephalomyelitis/chronic fatigue syndrome". Quality of Life Research. 26: 913–921. doi:10.1007/s11136-016-1406-3. PMC 5336422. PMID 27600520.
  23. ↑ Harvey, Jeanna M.; Broderick, Gordon; Bowie, Alanna; Barnes, Zachary M.; Katz, Ben Z.; O'Gorman, Maurice R.G.; Vernon, Suzanne D.; Fletcher, Mary Ann; Klimas, Nancy G. (April 26, 2016). "Tracking post-infectious fatigue in clinic using routine Lab tests". BMC Pediatrics. 15: 54. doi:10.1186/s12887-016-0596-8. ISSN 1471-2431. PMC 4847210. PMID 27118537.
  24. ↑ Deftereos, S. N.; Vernon, S. D.; Persidis, A. (2016). "Current therapeutic strategies for myalgic encephalomyelitis/chronic fatigue syndrome: results of an online survey". Fatigue: Biomedicine, Health & Behavior. 4 (1): 39–51. doi:10.1080/21641846.2015.1126025.
  25. ↑ Landi, Abdolamir; Broadhurst, David; Vernon, Suzanne D.; Tyrrell, D. Lorne J.; Houghton, Michael (February 2016). "Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome". Cytokine. 78: 27–36. doi:10.1016/j.cyto.2015.11.018.
  26. ↑ de Vega, Wilfred C.; Herrera, Santiago; Vernon, Suzanne D.; McGowan, Patrick O. (2017). "Epigenetic modifications and glucocorticoid sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". BMC Med Genomics. 10: 11. doi:10.1186/s12920-017-0248-3. PMC 5324230.
  27. ↑ Cook, Dane B.; Light, Alan R.; Light, Kathleen C.; Broderick, Gordon; Shields, Morgan R.; Dougherty, Ryan J.; Meyer, Jacob D.; VanRiper, Stephanie; Stegner, Aaron J.; Ellingson, Laura D.; Vernon, Suzanne D. (2017). "Neural Consequences of Post-Exertion Malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Brain, Behavior, and Immunity. 62: 87–99. doi:10.1016/j.bbi.2017.02.009.
  28. ↑ Uhde, M; Indart, AC; Fallon, BA; Wormser, GP; Marques, AR; Vernon, SD; Alaedini, A (2018). "C-reactive protein response in patients with post-treatment Lyme Disease symptoms versus those with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Clin Infect Dis. 67 (8): 1309–1310. doi:10.1093/cid/ciy299. PMC 6160605. PMID 29741589.
  29. ↑ de Vega, Wilfred C.; Erdman, Lauren; Vernon, Suzanne D.; Goldenberg, Anna; McGowan, Patrick O. (2018). "Integration of DNA methylation & health scores identifies subtypes in myalgic encephalomyelitis/chronic fatigue syndrome". Epigenomics. 10 (5): 539–557. doi:10.2217/epi-2017-0150.
  30. ↑ Uhde, M; Indart, AC; Yu, XB; Jang, SS; De Giorgio, R; Green, PHR; Volta, U; Vernon, SD; Alaedini, A (2018). "Markers of non-coeliac wheat sensitivity in patients with myalgic encephalomyelitis/chronic fatigue syndrome". Gut. 68: 377–378. doi:10.1136/gutjnl-2018-316133.
  31. ↑ Herrera, S; de Vega, WC; Ashbrook, D; Vernon, SD; McGowan, PO (December 2018). "Genome-epigenome interactions associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Epigenetics. 13 (12): 1174–1190. doi:10.1080/15592294.2018.1549769. PMID 30516085.
  32. ↑ Karhan, Ece; Gunter, Courtney L; Ravanmehr, Vida; Horne, Meghan; Kozhaya, Lina; Renzullo, Stephanie; Placek, Lindsey; George, Joshy; Robinson, Peter N; Vernon, Suzanne D.; Bateman, Lucinda; Unutmaz, Derya (December 26, 2019). "Perturbation of effector and regulatory T cell subsets in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". biorxiv. doi:10.1101/2019.12.23.887505.
  33. ↑ Lee, Jihyun; Vernon, Suzanne D.; Jeys, Patricia; Ali, Weam; Campos, Andrea; Unutmaz, Derya; Yellman, Brayden; Bateman, Lucinda (December 2020). "Hemodynamics during the 10-minute NASA Lean Test: evidence of circulatory decompensation in a subset of ME/CFS patients". Journal of Translational Medicine. 18 (1): 314. doi:10.1186/s12967-020-02481-y. ISSN 1479-5876. PMC 7429890. PMID 32799889.

Chronic Fatigue and Immune Dysfunction Syndrome (CFIDS) - Chronic Fatigue and Immune Dysfunction Syndrome is another term for Chronic Fatigue Syndrome, but one which emphasizes the immunological aspects of the disease. Popular in the 1990s, this term has apparently fallen into disuse.

Centers for Disease Control and Prevention (CDC) - The Centers for Disease Control and Prevention is a U.S. government agency dedicated to epidemiology and public health. It operates under the auspices of the Department of Health and Human Services.

blinded trial A clinical trial is blinded if either the participants or the researchers don't know which treatment group they are allocated to until after the results are interpreted. (Learn more: www.nottingham.ac.uk)

subjective outcome An outcome of a clinical trial that depends on the judgement or opinion of the assessor or patient, e.g. asking if fatigue has increased or decreased "a little" or "a lot", patient questionnaires like the Chalder Fatigue Scale, and other patient-reported outcome measures (PROMs).

genome an organism's complete set of DNA, including all of its genes

epigenome all of the chemical compounds that are not part of the DNA sequence, but are on or attached to DNA as a way to regulate gene activity

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

BMJ The BMJ (previously the British Medical Journal) is a weekly peer-reviewed medical journal.

cytokine any class of immunoregulatory proteins secreted by cells, especially immune cells. Cytokines are small proteins important in cell signaling that modulate the immune system. (Learn more: me-pedia.org)

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.

Retrieved from "https://me-pedia.org/index.php?title=Suzanne_Vernon&oldid=240130"